Pylarify injection
Ended Awarded Last action
- Contract number
- 36C25724F0057
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $569,928
Award facts
- Contract value 100% obligated
- $569,928.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- Q999 Medical- Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Antonio, TX 78229, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$172,628 | |
| Original award | $742,556 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 17, awarded a delivery order to Progenics Pharmaceuticals Inc. (a division of Lantheus Medical Imaging, Inc.) for a decreased quantity of PYLARIFY Injection with a firm fixed-price contract ceiling of approximately $570K. The award, dated January 18, 2024, with an ultimate completion date of January 17, 2025, represents a modification to reduce the previously ordered quantity of this critical radiopharmaceutical. This delivery order was issued without a set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and will be performed in San Antonio, Texas.
PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer. This award reflects the VA's ongoing procurement of specialized radiopharmaceuticals to support diagnostic imaging programs across its medical facilities. Progenics Pharmaceuticals, as a subsidiary of Lantheus Holdings, maintains substantial indefinite delivery vehicles with the VA and Defense Health Agency, including a $290 million Federal Supply Schedule contract running through March 2030, enabling consistent supply of critical medical imaging products to federal healthcare providers.
Quick answers
Who was awarded contract 36C25724F0057?
36C25724F0057 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 17 (Veterans Health Administration) on January 18, 2024.
How much is contract 36C25724F0057 worth?
The government has obligated $569,928 on 36C25724F0057.
Is contract 36C25724F0057 an order under another contract?
Yes. 36C25724F0057 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25724F0057 competed?
The extent of competition for 36C25724F0057 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award